CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trial
CRVO•New AAIC 2026 analyses support Phase 3 dose selection
CervoMed presented new AAIC 2026 analyses supporting 50 mg three-times-daily neflamapimod as the planned Phase 3 dose in dementia with Lewy bodies.
- Exploratory RewinD-LB results linked benefit to “pure” DLB patients with plasma pTau181 <21 pg/mL and trough concentrations near 4 ng/mL.
- Extension data showed better CDR-SB change with higher-exposure capsules: 0.17 worsening vs 0.95 on prior placebo in the same patients (p=0.005).
- MRI analyses showed slowed right basal forebrain atrophy over 48 weeks, with increased basal forebrain–default mode network connectivity during the extension.
Open-label Phase 2 study met safety and pharmacokinetic goals
An open-label Phase 2 study of 80 mg twice daily met safety, tolerability, and pharmacokinetic goals over 24 weeks in 26 patients.
